Context Therapeutics Inc (CNTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.24+1.57%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Context Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.113
Annual ending 2026-12-31
Revenue	—	2M
EPS	—	-0.461
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-0.434

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Successful commercialization of BioAtla antibody assets	Context Therapeutics secured exclusive rights to antibody assets via a BioAtla license amendment in May 2026.	Improving	no meaningful progress toward commercialization milestones by FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improvement in EPS losses	A supporting condition in Context Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -$0.43 in 2027 to less negative by FY28.	Broken	EPS loss worsens beyond -$0.43 in FY27 or fails to improve in FY28	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolution of stockholder litigation and Nasdaq listing compliance	A primary condition in Context Therapeutics Inc's published investment case. The stated target is complete resolution of litigation and maintain Nasdaq listing by end 2026.	Under Pressure	litigation escalates or Nasdaq delisting occurs in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.43

$-0.43 → $-0.43 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.43	$0	7 / 8
2026-07-25	$-0.43	$0	7 / 8
2026-07-26	$-0.43	$0	7 / 8
2026-07-27	$-0.43	$0	7 / 8
2026-07-28	$-0.43	$0	7 / 8
2026-07-29	$-0.43	Unavailable	6 / 0
2026-07-30	$-0.43	$0	7 / 8
2026-07-31	$-0.43	$0	7 / 8
2026-08-01	$-0.43	Unavailable	6 / 0
2026-08-02	$-0.43	$0	7 / 8
2026-08-03	$-0.43	$0	7 / 8
2026-08-04	$-0.43	$0	7 / 8
2026-08-05	$-0.43	Unavailable	6 / 0
2026-08-06	$-0.43	Unavailable	6 / 0
2026-08-07	$-0.40	Unavailable	6 / 0
2026-08-08	$-0.45	$0	7 / 8
2026-08-09	$-0.45	$0	7 / 8
2026-08-10	$-0.40	Unavailable	6 / 0
2026-08-11	$-0.40	Unavailable	6 / 0
2026-08-12	$-0.40	Unavailable	6 / 0
2026-08-13	$-0.41	$0	7 / 8
2026-08-14	$-0.40	Unavailable	6 / 0
2026-08-15	$-0.40	Unavailable	6 / 0
2026-08-16	$-0.40	Unavailable	6 / 0
2026-08-17	$-0.40	Unavailable	6 / 0
2026-08-18	$-0.40	Unavailable	6 / 0
2026-08-19	$-0.40	Unavailable	6 / 0
2026-08-20	$-0.41	Unavailable	6 / 0
2026-08-21	$-0.41	Unavailable	6 / 0
2026-08-22	$-0.43	Unavailable	6 / 0
2026-08-23	$-0.43	Unavailable	6 / 0
2026-08-24	$-0.43	Unavailable	6 / 0
2026-08-25	$-0.43	Unavailable	6 / 0
2026-08-26	$-0.43	Unavailable	6 / 0
2026-08-27	$-0.43	Unavailable	6 / 0
2026-08-28	$-0.43	Unavailable	6 / 0
2026-08-29	$-0.43	Unavailable	6 / 0
2026-08-30	$-0.43	Unavailable	6 / 0
2026-08-31	$-0.43	Unavailable	6 / 0
2026-09-01	$-0.43	Unavailable	6 / 0
2026-09-02	$-0.43	Unavailable	6 / 0
2026-09-03	$-0.43	Unavailable	6 / 0
2026-09-04	$-0.43	Unavailable	6 / 0
2026-09-05	$-0.43	Unavailable	6 / 0
2026-09-06	$-0.43	Unavailable	6 / 0
2026-09-07	$-0.43	Unavailable	6 / 0
2026-09-08	$-0.43	Unavailable	6 / 0
2026-09-09	$-0.43	Unavailable	6 / 0
2026-09-10	$-0.43	Unavailable	6 / 0
2026-09-11	$-0.43	Unavailable	6 / 0
2026-09-12	$-0.43	Unavailable	6 / 0
2026-09-13	$-0.43	Unavailable	6 / 0
2026-09-14	$-0.43	Unavailable	6 / 0
2026-09-15	$-0.43	Unavailable	6 / 0
2026-09-16	$-0.43	Unavailable	6 / 0
2026-09-17	$-0.43	Unavailable	6 / 0
2026-09-18	$-0.43	Unavailable	6 / 0
2026-09-19	$-0.43	Unavailable	6 / 0
2026-09-20	$-0.43	Unavailable	6 / 0
2026-09-21	$-0.43	Unavailable	6 / 0
2026-09-22	$-0.43	Unavailable	6 / 0
2026-09-23	$-0.43	Unavailable	6 / 0
2026-09-24	$-0.43	Unavailable	6 / 0
2026-09-25	$-0.43	Unavailable	6 / 0
2026-09-26	$-0.43	Unavailable	6 / 0
2026-09-27	$-0.43	Unavailable	6 / 0
2026-09-28	$-0.43	Unavailable	6 / 0
2026-09-29	$-0.43	Unavailable	6 / 0
2026-09-30	$-0.43	Unavailable	6 / 0
2026-10-01	$-0.43	Unavailable	6 / 0
2026-10-02	$-0.43	Unavailable	6 / 0
2026-10-03	$-0.43	Unavailable	6 / 0
2026-10-04	$-0.43	Unavailable	6 / 0
2026-10-05	$-0.43	Unavailable	6 / 0
2026-10-06	$-0.43	Unavailable	6 / 0
2026-10-07	$-0.43	Unavailable	6 / 0
2026-10-08	$-0.43	Unavailable	6 / 0
2026-10-09	$-0.43	Unavailable	6 / 0
2026-10-10	$-0.43	Unavailable	6 / 0
2026-10-11	$-0.43	Unavailable	6 / 0
2026-10-12	$-0.43	Unavailable	6 / 0
2026-10-13	$-0.43	Unavailable	6 / 0
2026-10-14	$-0.43	Unavailable	6 / 0
2026-10-15	$-0.43	Unavailable	6 / 0
2026-10-16	$-0.43	Unavailable	6 / 0
2026-10-17	$-0.43	Unavailable	6 / 0
2026-10-18	$-0.43	Unavailable	6 / 0
2026-10-19	$-0.43	Unavailable	6 / 0
2026-10-20	$-0.43	Unavailable	6 / 0
2026-10-21	$-0.43	Unavailable	6 / 0
2026-10-22	$-0.43	Unavailable	6 / 0
2026-10-23	$-0.43	Unavailable	6 / 0
2026-10-24	$-0.43	Unavailable	6 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	0
2026-06-01	10	0
2026-07-01	10	0
2026-08-01	10	1
2026-09-01	9	1
2026-10-01	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Successful commercialization of BioAtla antibody assetsDirect metric needs a verified mapping
Improvement in EPS lossesPublished status: Broken
Resolution of stockholder litigation and Nasdaq listing compliancePublished status: Under Pressure

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-93.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Context Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage biotechnology, not a business with established earnings: it is loss-making, recent financial performance is weak, and overall risk is high. The thesis is on watch, with low confidence, as clinical programs show some progress but legal and listing issues remain unresolved.

What's priced into Context Therapeutics Inc

The evidence provides no valuation measure or clear account of market expectations, so whether CNTX is cheap, fair, or expensive versus peers is unclear. Its loss-making status and high risk are evident, but the expectations gap cannot be assessed from this snapshot.

What the fundamentals likely do

Near-term results remain uncertain, with an elevated risk of an earnings miss; the evidence attributes this in part to CNTX's small size and its industry's high miss rate. Over the multi-year view, CTIM-76 development has reported interim safety and efficacy signals, while CT-202's planned trial timing is consistent with management's stated timeline. Legal challenges and the minimum-bid listing notice remain material execution risks.

What Context Therapeutics Inc hinges on

The multi-year thesis depends on whether CTIM-76 and CT-202 can advance through clinical development and show meaningful progress. Near-term sector conditions are a secondary swing factor: strong results and guidance from healthcare bellwethers could sustain a sector tailwind, while weaker reports could remove it. Continued weakness in employment data could also add pressure to cyclical and healthcare names.